Octreotide Injection

342 interactions 555 cited references
Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot
About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone
13 Contraindicated 325 Major 4 Moderate
All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Insulin Degludec Tresiba An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Insulin Detemir Levemir An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Insulin Glargine, Recombinant Basaglar An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Insulin Glulisine Apidra An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Insulin Icodec-Abae Awiqli An increased risk of hypoglycemia Details Octreotide Injection Insulin Lispro, Recombinant Admelog An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Isoflurane Fluriso An increased risk of QT prolongation and torsades de pointes Details Octreotide Injection Isradipine DynaCirc® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Itraconazole Sporanox An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Ivabradine Corlanor Increased risk of QT prolongation Details Octreotide Injection Ivosidenib Tibsovo An increased risk of QT interval prolongation Details Octreotide Injection Ketoconazole Extina Increased risk of QT interval prolongation Details Octreotide Injection Lansoprazole Prevacid Decreased octreotide bioavailability Details Octreotide Injection Lapatinib Tykerb An increased risk of QT interval prolongation Details Octreotide Injection Lefamulin Xenleta Increased risk of QT interval prolongation Details Octreotide Injection Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Octreotide Injection Leuprolide Eligard Increased risk of QT interval prolongation Details Octreotide Injection Levofloxacin Levaquin Increased risk of QT interval prolongation Details Octreotide Injection Levonorgestrel After banger Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Lidoflazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Linagliptin Tradjenta An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Liraglutide Saxenda An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Lixisenatide An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Lofexidine Increased risk of QT interval prolongation Details Octreotide Injection Lomitapide Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Lonafarnib Zokinvy An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Octreotide Injection Lopinavir An increased risk of QT interval prolongation Details Octreotide Injection Lorcainide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Lumefantrine An increased risk of QT interval prolongation Details Octreotide Injection Lutetium Lu 177 Dotatate Decreased lutetium Lu 177 dotatate efficacy Details Octreotide Injection Macimorelin Increased risk of QT interval prolongation Details Octreotide Injection Magaldrate Decreased octreotide bioavailability Details Octreotide Injection Magnesium Carbonate Decreased octreotide bioavailability Details Octreotide Injection Magnesium Hydroxide Almacone® (containing Aluminum Hydroxide, Magnesium Hydroxide, Simethicone) Decreased octreotide bioavailability Details Octreotide Injection Magnesium Oxide Mag-Ox 400 Decreased octreotide bioavailability Details Octreotide Injection Magnesium Peroxide Decreased octreotide bioavailability Details Octreotide Injection Magnesium Trisilicate Decreased octreotide bioavailability Details Octreotide Injection Mavorixafor Xolremdi An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Mefloquine Lariam® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.